Session Information

  • WCLC 2021

    2021 World Conference on Lung Cancer

    Conference Program for 2021 the World Conference on Lung Cancer

    Presentation Date(s):  
    • September 8 - 14, 2021
    • Total Presentations: 1107

    All times listed are in Mountain Time MDT (UTC-6:00)

    PL - Plenary
    ES - Education Session
    OA - Oral Session
    MA - Mini Oral Session
    FP - Featured Posters
    P - Posters
    WS - Workshops
    IS - Industry Symposium
    MTE - Meet the Expert
    BEDG - Brain Exchange Discussion Groups

Filter Results:

Show Only CME Accredited Sessions

  • +

    OA01 - The Impact of COVID-19 on Patients with Lung Cancer

    • 08:15 - 09:15
    • 9/08/2021
    • Location: Program Auditorium
    • IASLC CME Accredited
    • Type: Oral
    • Track: Management of Lung Cancer in the Era of COVID-19
    • +

      OA01.01 - Analysis of Lung Cancer Patients Receiving SARS-CoV-2 Vaccines Revealed a Minority Subset With Poor Antibody Responses Relative to Controls

      08:15 - 08:25  |  Presenter: Jorge E Gomez

      • Abstract

      Loading...

    • +

      OA01.02 - Impact of COVID-19 Outbreak on Lung Cancer Diagnosis and Continuum of Care: Data From an Italian Multicenter Study

      08:25 - 08:35  |  Presenter: Luca Cantini

      • Abstract

      Loading...

    • +

      OA01.03 - Immune Checkpoint Inhibitor Dose Adaptation During the COVID-19 Pandemic in Non-Small Cell Lung Cancer– a Single-Center Experience

      08:35 - 08:45  |  Presenter: Lucie Brigitte Marie Hijmering-Kappelle

      • Abstract

      Loading...

    • +

      OA01.04 - Discussant

      08:45 - 08:55  |  Presenter: Suresh Ramalingam

      • Abstract

      No abstract available for this presentation

    • +

      OA01.05 - Live Discussion with Speakers

      08:55 - 09:05

      • Abstract

      No abstract available for this presentation

  • +

    MA04 - Current Status and Future Prospects of Pleural Mesothelioma and Thymoma

    • 10:45 - 11:45
    • 9/08/2021
    • Location: Program Auditorium
    • IASLC CME Accredited
    • Type: Mini Oral
    • Track: Mesothelioma, Thymoma and Other Thoracic Malignancies
    • +

      MA04.07 - Clinical Characteristics and Outcomes in Patients With Malignant Pleural Mesothelioma (MPM) with COVID-19 Infection

      11:25 - 11:30  |  Presenter: Susana Cedres

      • Abstract

      Loading...

  • +

    FP09 - Novel Therapeutics and Targeted Therapies

    • 00:00 - 00:00
    • 9/08/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters (Featured)
    • Track: Novel Therapeutics and Targeted Therapies
    • +

      FP09.01 - Mobocertinib in Platinum-Pretreated EGFR Exon 20 Insertion+ Metastatic NSCLC Patients With/Without Prior Anti-PD(L)-1 Therapy

      00:00 - 00:00  |  Presenter: Pasi A. Janne

      • Abstract

      Loading...

  • +

    P45 - Novel Therapeutics and Targeted Therapies - ALK/ROS1/MET

    • 00:00 - 00:00
    • 9/08/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Novel Therapeutics and Targeted Therapies
    • +

      P45.03 - Tepotinib in Patients with MET exon 14 (METex14) Skipping NSCLC as Identified by Liquid (LBx) or Tissue (TBx) biopsy

      00:00 - 00:00  |  Presenter: Enriqueta Felip

      • Abstract

      Loading...

  • +

    PL02 - Plenary 2: Presidential Symposium (Japanese, Mandarin, Spanish Translation Available)

    • 06:30 - 08:00
    • 9/09/2021
    • Location: Program Auditorium
    • IASLC CME Accredited
    • Type: Plenary
    • Track: N.A.
    • +

      PL02.05 - IMpower010: Characterization of Stage IB-IIIA NSCLC Patients by Type and Extent of Therapy Prior to Adjuvant Atezolizumab

      07:04 - 07:14  |  Presenter: Nasser Altorki

      • Abstract

      Loading...

  • +

    OA09 - Expanding Immunotherapy Options for Non-Small Cell Lung Cancers

    • 09:30 - 10:30
    • 9/09/2021
    • Location: Program Auditorium
    • IASLC CME Accredited
    • Type: Oral
    • Track: Immunotherapy (Phase II/III Trials)
    • +

      OA09.01 - First-line Nivolumab + Ipilimumab + Chemo in Patients With Advanced NSCLC and Brain Metastases: Results From CheckMate 9LA

      09:30 - 09:40  |  Presenter: David Carbone

      • Abstract

      Loading...

    • +

      OA09.02 - Atezo-Brain: Single Arm Phase II Study of Atezolizumab Plus Chemotherapy in Stage IV NSCLC With Untreated Brain Metastases

      09:40 - 09:50  |  Presenter: Ernest Nadal

      • Abstract

      Loading...

  • +

    PL02A - Plenary 2: Presidential Symposium (Rebroadcast) (Japanese, Mandarin, Spanish Translation Available)

    • 14:30 - 16:00
    • 9/09/2021
    • Location: Program Auditorium
    • IASLC CME Accredited
    • Type: Plenary
    • Track: N.A.
    • +

      PL02A.05 - IMpower010: Characterization of Stage IB-IIIA NSCLC Patients by Type and Extent of Therapy Prior to Adjuvant Atezolizumab

      15:04 - 15:14  |  Presenter: Nasser Altorki

      • Abstract

      Loading...

  • +

    MA14 - Pathologic Patterns, Genomic Alterations and Targeted Therapies in NSCLC

    • 18:45 - 19:45
    • 9/13/2021
    • Location: Program Auditorium
    • IASLC CME Accredited
    • Type: Mini Oral
    • Track: Predictive Tumor Based Assays/ Biomarkers/ Pathology
    • +

      MA14.02 - RET Fusion Testing in Advanced Non-Small Cell Lung Carcinoma Patients: the RETING Study

      18:50 - 18:55  |  Presenter: Fernando Lopez-Rios

      • Abstract

      Loading...